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ABSTRACT
Renal patients are overexposed to hepatitis C
virus (HCV) infection. Hepatitis C virus infection
may induce renal disease, i.e., cryoglobulinemic
membrano-proliferative glomerulopathy and
non-cryoglobulinemic nephropathy. Hepatitis
C virus impacts general outcomes in chronic
kidney disease, dialysis or transplanted patients.
Hepatitis C virus infection is now about to be
only part of their medical history thanks to new
direct acting antiviral drugs exhibiting as much
as over 95% of sustained virological response. All
HCV-infected patients potentially can receive
the treatment. Control of the virus is associated
with better outcomes in all cases, whatever the
severity of the hepatic or renal disease. This
article focuses on HCV-induced renal diseases,
the reciprocal impact of HCV infection on the
renal outcome and renal status in liver disease,
use of new direct-acting antiviral drugs with
dosage adaptations and the most recent safety
data.
Keywords: Chronic kidney disease;
Cryoglobulinemia; Dialysis; Direct acting
antiviral agents; Hepatitis C;
Membranoproliferative glomerulonephritis;
Sustained virological response; Transplantation
INTRODUCTION
Hepatitis C virus (HCV) was discovered 25 years
ago [1] and is now about to get a cure. In the
meantime, the C virus has induced tremendous
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morbidity and mortality mainly due to liver
complications (cirrhosis, hepatocellular
carcinoma). However, many extrahepatic
manifestations [2] have been reported for
chronic HCV infection with increased related
morbidity and mortality, including
cardiovascular diseases, type 2 diabetes and
insulin resistance, neurocognitive dysfunction,
systemic vasculitis, B cell non-Hodgkin
lymphoma and chronic kidney disease [3].
Today, some new challenges remain,
particularly with regard to specific populations
suffering from HCV infection, such as renal
patients. Our article focuses on the specificities
of screening, monitoring, assessing, treating
and following up, in the context of HCV
infection, persons living with chronic kidney
disease, end-stage renal failure or a kidney graft.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
EPIDEMIOLOGY OF HEPATITIS C
VIRUS INFECTION IN RENAL
PATIENTS
Approximately 170 million people are infected
with HCV worldwide and 2.35% of the total
world population [4]. In dialysis patients, the
prevalence of HCV infection has evolved
dramatically over the last 10 years. In 2004,
the Dialysis Outcomes and
Practice Patterns Study (DOPPS) published the
largest study analyzing the HCV serological
status in 8615 randomly selected hemodialysis
patients treated in 308 dialysis facilities (in 8
countries in Europe, HCV USA and Japan) [5]. It
showed the HCV antibody prevalence to be
14.7% when unadjusted and 10.4% when
adjusted for age, gender, race, time with
end-stage renal disease, and alcohol or drug
abuse in the past 12 months. The updated
DOPPS study [6] found a very low prevalence
of HCV treatment in dialysis patients as only
1% of the 4589 patients with available
prescription data were receiving HCV
medications. Among a subset of 617 HCV
patients known to be on the waiting list for
renal transplantation, only 3.7% were receiving
HCV treatment. In the DOPPS study, the
seropositivity for HCV was associated with
black race [odds ratio (OR) = 1.93, P\0.0001],
male gender (OR = 1.18, P = 0.01), diabetes
mellitus (OR = 1.18, P = 0.03), a history of
gastrointestinal bleeding (OR = 1.22, P = 0.06),
HBV infection (OR = 2.56, P\0.0001) and prior
renal transplant (OR = 1.34, P = 0.01). Drug
and alcohol abuse, as reported during the
12 months prior to data collection, was also
associated with HCV seropositivity (OR = 2.44,
P\0.0001 and 1.75, P = 0.0001, respectively).
At that time, the risk of seroconversion was
variable despite infection control measures, and
HCV outcomes varied by patient characteristics,
country and hemodialysis facility practice
patterns. No consensus was available with
regard to the need for hemodialysis patient
isolation and dedicated dialysis machines to
prevent HCV transmission, in addition to
blood-borne precautions [5]. Adjusted HCV
seroconversions/100 patient-years ranged from
1.2 (0.7–2.0) in the UK to 3.9 (2.9–5.2) in Italy.
In 55.6% of facilities, the mean seroconversion
rate was 0 per 100 patient-years. Seroconversion
was mostly associated with the prevalence of
HCV in the facility and with black race [relative
risk (RR) = 1.42, P = 0.05], duration of end-stage
renal disease (ESRD) therapy by year [with a 4%
higher risk of seroconversion (P = 0.007)] and
HIV/AIDS or HBV co-infection (RR = 3.29,
P = 0.006 and RR = 2.16, P = 0.001,
respectively). The authors concluded that this
study provided evidence for nosocomial
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transmission of HCV in dialysis facilities but did
not demonstrate that isolation of patients
infected with HCV was associated with a
decreased risk of HCV seroconversion. The
major drawback in this work was the absence
of HCV RNA analysis.
A more recent analysis, the DOPPS 5 study
(2012–2015) [6], included around 500 facilities
and 17,000 patients in 21 countries. It showed
that HCV prevalence among hemodialysis
patients has declined in recent years in many
DOPPS countries but remains higher than in the
general population with a prevalence of 9.5%
(in 11,394 patients). We generated the most
recent analysis of the prevalence and incidence
of HCV and HBV infections in end-stage renal
disease patients in France from the REIN
registry, a national prospective cohort
including 72,948 patients who started dialysis
or were preemptively transplanted. We found
significantly lower prevalence of both HBV
[1.41% (95% CI 1.32–1.49)] and HCV infection
[0.84% (95% CI 0.78–0.91)] [7].
Transplanted patients are also exposed to
HCV infection, mostly through their treatment
with dialysis. However, a decrease in the
frequency of HCV infection during dialysis has
been mirrored by a decreased rate of HCV
infection acquisition following renal
transplantation [8].
CLINICAL INVOLVEMENT
OF KIDNEY DURING HEPATITIS C
VIRUS INFECTION
Mixed Cryoglobulinemia Vasculitis
Mixed cryoglobulinemia vasculitis (CryoVas)
[9]—a small vessel vasculitis involving mainly
the skin, joints, peripheral nerve system and
kidneys—is mainly due to HCV infection
(70–80% of cases). The CryoVas may express
mild symptoms (purpura, arthralgia) or more
severe life-threatening complications
(glomerulonephritis, widespread vasculitis).
Renal involvement is an acute or chronic type-I
membranoproliferative glomerulonephritis
(GNMP) with subendothelial deposits (70–80%
of cases), and it is strongly associated with type II
IgM kappa mixed cryoglobulinemia [10].
Patients present with proteinuria, microscopic
hematuria, a variable degree of renal
insufficiency and new-onset arterial
hypertension. Acute nephrotic or nephritic
syndrome can also reveal CryoVas renal
involvement. Early serum complement
component levels (C1q, C4) are very low.
Chronic renal insufficiency may develop in
10–20% of HCV-CryoVas patients. The
pathological features are characterized by
important monocyte infiltrates with double
contours of the basement membrane and large,
eosinophilic and amorphous intraluminal
thrombi. Indirect immunofluorescence shows
intraglomerular subendothelial deposits of IgG,
IgM and complement components.
Cryoglobulinemia is confirmed by the
detection of protein precipitates in the
patient’s serum maintained at 4 C for at least
7 days, which dissolved when heated at 37 C.
Biological improvement can be assessed by the
quantification of cryoglobulinemia and C4 and
CH50 levels [9]. During HCV infection,
predictive factors for CryoVas are advanced
age, longer duration of infection, type II
mixed cryoglobulinemia, higher cryoglobulin
serum levels and clonal B cell expansions in
both the blood and liver [11]. The overall 5-year
survival after the diagnosis of HCV-CryoVas
ranges from 90% to 50%, the latter being
reported in case of renal involvement [11–14].
In a retrospective Italian study of 231
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HCV-CryoVas patients [12], 79 of 97 deaths
were linked to vasculitis (46%, of which
one-third were due to renal involvement).
Life-threatening CryoVas complications are
observed in up to 10% of the patients with
almost two-thirds resulting in death [13].
HCV-CryoVas may result in progressive (renal
involvement) or acute (pulmonary hemorrhage,
gastrointestinal ischemia, cardiac, CNS
involvement) life-threatening organ damage.
The mortality rate of these manifestations
ranges between 20% and 80% [14, 15]. Age
older than 60 years at diagnosis, the presence of
a renal failure, intestinal ischemia, pulmonary
hemorrhage, high cryocrit levels and type II
mixed cryoglobulinemia are associated with
severe prognosis [13].
In HCV-infected patients, many factors have
been described to predispose patients to a
CryoVas. Interaction between the virus and
immune cells directly modulates B- and T-cell
function resulting in expansion of B-cell
production of IgM with RF activity [16]. The
CD4?CD25?FoxP3? regulatory T cell number is
significantly reduced [17, 18], possibly leading to
the expansion of peripheral auto-reactive B-cells.
HLA-DR11 is associated with HCV-CryoVas,
whereas HLA-DR7 appears to protect patients
from the production of type II mixed
cryoglobulinemia [19]. In a large multicenter
study significant associations were identified on
chromosome 6, a SNP located within an intronic
region of NOTCH4 (p = 6.2 9 10-9), and another
was found in between HLA-DRB1 and
HLA-DQA1 (p = 1.2 9 10-7) [20]. A higher
percentage of a particular allele of the promoter
of the B-cell activating factor and different
expression patterns on circulating lymphocytes
of microRNAs known to be involved in
lymphoproliferative and/or autoimmune
disorders have been shown [21, 22]. Specific
virological factors have never been identified.
Non-Cryoglobulinemic Renal
Involvement in HCV-Infected Patients
Other glomerular diseases in both native [23]
and transplanted kidneys [24] have been more
rarely reported. In a large case-control study in
US hospitalized male veterans [25], there was a
greater proportion of MPGN among patients
with HCV (0.36% vs. 0.05%, p\0.0001), but
not of membranous glomerulopathy.
HCV-infected patients showed a 40% higher
prevalence of renal insufficiency compared with
non-HCV-infected people [26]. Other large
surveys also suggested an impact of HCV
infection on the prevalence and incidence of
kidney disease in the general population
[26–30]. The HCV seropositive status was
associated with low GFR (OR up to 2.80) and
proteinuria (OR 1.14–1.99), independently of
diabetes mellitus, arterial hypertension, obesity
and dyslipidemia [31]. In a recent
population-based cohort among 2,267,270
Taiwanese residents diagnosed with diabetes
mellitus [32], the cumulative incidences of
ESRD at 8 years in the HCV-treated,
HCV-untreated and uninfected cohorts were
1.1%, 9.3% and 3.3%, respectively. As
compared with the untreated cohort, HCV
treatment was associated with an HR of 0.16
(0.07–0.33%) for ESRD. Recent information has
also accumulated on the association between
HCV and glomerular disease in the liver [33, 34]
or kidney/liver [35] transplanted population.
The natural history of these HCV-associated
nephropathies is characterized by remission and
relapsing phases. Finally, HIV-HCV coinfection
was also linked with a significant increase in the
risk of HIV-related kidney disease [36, 37].
The Kidney Disease Improving Global
Outcomes (KDIGO) group recommends that
all patients with chronic kidney disease should
be tested for HCV [38]. The KDIGO also
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recommended that patients with acute flares of
CryoVas and MPGN be treated with IFN-based
HCV treatment. No doubt with recent advances
in HCV treatment and direct-acting agents
(DAAs) on the market such recommendations
should be updated, i.e., should recommend
IFN-free HCV treatment for patients with
CryoVas and MPGN. In HCV-CryoVas patients
with kidney involvement, the addition of
rituximab to antivirals showed greater renal
response rates than antivirals alone [39, 40].
However, considering the great and very rapid
virological efficacy of DAAs, the remaining
place of rituximab in HCV-MPGN needs to be
further studied.
Impact of CKD on Hepatitis C Outcomes
Several studies have demonstrated that dialysis
is associated with an increased risk of all-cause
and liver-related mortality [41–43]. In this
population, cardiovascular disease remains the
first cause for death. CKD always impacts the
treatment of chronic diseases negatively
because of the poorer drug tolerance, higher
prevalence of side effects and complexity of
drug dosage adaptation. Hepatitis C treatment
has long been offered through peginterferon
alpha associated with ribavirin with very poor
tolerance and a high prevalence of anemia and
depressive syndrome leading to anticipated
resuming of therapy [42]. Of note,
HCV-Cryovas patients who present a GNMP
showed a lower response rate to IFN-based
treatment, whereas they showed a higher
benefit of rituximab.
In transplanted patients,
immunosuppression has been associated with
an increase of serum HCV-RNA levels [43], and
contradictory results emerged from the
histological data on hepatic fibrosis after
kidney transplantation. Some observations
reported dramatically bad outcomes after
kidney transplantation with fibrosing
cholestatic hepatitis [44]. Survival after
transplantation was reported to be impacted
negatively by a predisposition to progressive
liver disease [8]. Besides, onset of new diabetes is
significantly increased after transplantation
potentially leading to metabolic complications.
TREATMENT OF HEPATITIS C
INFECTION
In Patients with HCV-CryoVas
The CryoVas manifestations respond
dramatically to HCV cure after antiviral
therapy with pegylated interferon (IFN) plus
ribavirin [45–48]. In case of persistent mixed
cryoglobulinemia after HCV cure, when relapse
of vasculitis also occurs, a different condition
should be considered, especially B-cell
lymphoma [49]. A recent open-label French
prospective study [50] showed the good
efficacy of a combination therapy with
Peg-IFN/ribavirin plus a NS3/4A protease
inhibitor (boceprevir or telaprevir) in patients
with HCV-CryoVas. At week 24 post-treatment,
two-thirds of patients were complete clinical
responders, and their HCV was cured. However,
serious adverse events occurred in half of the
patients. In a prospective Italian study [51],
HCV-CryoVas patients treated with Peg-IFN/
ribavirin/boceprevir for 48 weeks showed a
dramatic reduction in the cryocrit values and
improvement of CryoVas symptoms. Other
DAAs such as the NS5B inhibitor sofosbuvir,
NS3/4A inhibitor simeprevir and NS5A inhibitor
daclatasvir have been more recently licensed.
These agents facilitate the use of shortened
courses of combination IFN-free therapy,
showing SVR rates [95% and few toxicities.
International guidelines [52] recommend that
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treatment should be scheduled, not deferred,
for patients with clinically significant
extra-hepatic manifestations, like CryoVas. A
very recent open-label cohort study enrolled 24
patients with HCV-CryoVas who received an
all-oral IFN-free regimen with sofosbuvir
(400 mg/day) and ribavirin (200–1400 mg/day)
for 24 weeks [53]. At week 12 post-treatment,
85% of patients were in complete remission for
the CryoVas and 74% had an SVR, with a low
rate of serious adverse events. The cryoglobulin
level decreased from 0.35 to 0.15 g/l, while the
C4 serum level increased from 0.10 to 0.17 g/l.
Among patients with kidney involvement, renal
function improved in four out of five,
proteinuria decreased from 1.09 (0.6–2.4) to
0.17 (0.07–0.25) g/day and hematuria
disappeared in all cases. Another study
reported 12 HCV-Cryovas patients treated with
sofosbuvir-based regimens [54]. Median
baseline serum creatinine was 0.97 mg/dl
(range 0.7–2.47 mg/dl). Four patients received
rituximab concurrently with DAA therapy. The
SVR at 12 weeks post-treatment was 83%.
Patients with glomerulonephritis who
achieved SVR12 experienced an improvement
in serum creatinine and reduction in
proteinuria. Serious adverse events were
infrequent (17%). The historical cohort in this
study treated with pegylated-IFN and ribavirin
experienced a 10% SVR12 rate and 50%
experienced premature discontinuation due to
adverse events.
Rituximab targets B-cells, which are
responsible for cryoglobulin production and
finally vasculitic lesions [55–59]. In a
randomized controlled trial of HCV-CryoVas
patients, rituximab showed better efficacy than
immunosuppressive treatments or
plasmapheresis [60]. Similar results have been
reported in a placebo-controlled trial [61]. The
use of rituximab was shown to be safe in HCV
patients, in contrast with what was observed in
HBV-infected patients [62, 63]. Two controlled
clinical trials showed that rituximab plus
Peg-IFN/ribavirin compared to Peg-IFN/
ribavirin led to a shorter time to clinical
remission, better renal response rate and
higher rates of cryoglobulin clearance [39, 40].
However, there are no data indicating the exact
place of rituximab with the use of DAAs,
particularly if an IFN-free DAA combination is
used before or at the same time as rituximab
therapy.
Low-dose corticosteroids may help to control
arthralgia but do not succeed in case of major
organ involvement. Other
immunosuppressants should be given in case
of refractory HCV-CryoVas associated with
underlying B-cell lymphoma [64].
In CKD Patients and ESRD Patients
(Including Dialysis and Transplantation):
Use and Monitoring of DAAs
In the past decade, peginterferon and ribavirin
were considered the mainstay of hepatitis C
virus treatment in CKD patients despite a high
prevalence of side effects and poor clinical and
biological tolerance. New DAAs offer
dramatically improved efficacy in the general
population.
Hepatitis C treatment may be discussed at
any time of the follow-up when the glomerular
filtration rate decreases during dialysis
treatment, before and after renal
transplantation [65].
It is a matter of debate whether hepC therapy
should occur before or after transplantation
[65]. Drug-drug interactions will definitively
make monitoring more complex after
transplantation since the impact of DAAs on
tubular transports and cytochrome metabolisms
will dramatically impact the pharmacokinetic
318 Infect Dis Ther (2016) 5:313–327
properties of immunosuppressive drugs [66].
New strategies will now emerge with regard to
HCV treatment before or after renal
transplantation depending also on the
availability of a living donor or not. In case of
a living donor, it has been proposed that DDA’s
treatment should occur before transplantation
in order to obtain SVR12. When there is no
living donor available, some centers (with a
signed consent from the patient) will offer an
HCV-positive graft to the patient and begin
DAA treatment after transplantation, therefore
reducing waiting times significantly [65]. DAA’s
availability will definitely further change the
organ allocation criteria.
The information on the efficacy and safety of
DAAs for HCV therapy in patients with renal
failure is limited, but DAAs have begun to show
their indications in stage 4 and 5 CKD patients.
One of the available combinations of DAAs
approved for patients with 15\GFR\30 ml/
min is the paritaprevir/ritonavir plus ombitasvir
combination [67]. In this study, HCV genotype
1 treatment-naı¨ve patients (without cirrhosis)
were included in an open-label treatment study
if they had stage 4 or 5 CKD. Twenty patients
received DAAs for 12 weeks in two groups
(N = 7 for genotype 1a receiving the
paritaprevir/ritonavir plus ombitasvir
combination and N = 13 for genotype 1b
receiving the paritaprevir/ritonavir plus
ombitasvir plus ribavirin combination). Two
patients failed to achieve SVR12, and the
overall tolerance of the treatment was
satisfying. The choice of the appropriated drug
must take into account the viral genotype as
well as the tolerance in patients with decreased
GFR. It is noteworthy, for example, that the
paritaprevir/ritonavir/ombitasvir/dasabuvir
combination is approved for CKD only in
genotype 1 patients and that the paritaprevir/
ritonavir/ombitasvir combination is only
effective for HCV-4.
The other combination showing good
efficacy and tolerability in CKD settings is
described in the C-SURFER study [68]. In this
multicenter phase III all oral combination of
grazoprevir 100 mg/day (HCV NS3/4A
inhibitor) and elbasvir 50 mg/day (HCV NS5A
inhibitor), 99.1% SVR12 was obtained in HCV
genotype 1 patients with stage 4 and 5 CKD and
compensated cirrhosis. Treatment was generally
well tolerated. Less than 1% of grazoprevir and
elbasvir was renally excreted [69]. Patients
treated with hemodialysis were included in
this study, whereas no data have been
published on peritoneal dialysis patients. The
grazoprevir/elbasvir combination, with or
without ribavirin, was recently approved by
the FDA for the treatment of chronic HCV
genotype 1 and 4 infections in adult patients
and was granted breakthrough therapy
designation for the treatment of chronic HCV
genotype 1 infection in patients with end-stage
renal disease on hemodialysis and for the
treatment of chronic HCV genotype 4
infection [69, 70].
Other DAA combinations may be used in
CKD patients with well-preserved renal
function, such as sofosbuvir (NS5B polymerase
inhibitor) together with simeprevir (NS3/4A
protease inhibitor), daclatasvir or ledipasvir
(both NS5A inhibitors) with expected efficacy
comparable to that of the general population.
However, decreased renal function was
observed with sofosbuvir in patients with GFR
below 45 ml/min/1.73 m2 [70]. An active
metabolite of sofosbuvir is actively renally
secreted, and therefore overexposure may be
observed in CKD patients. Sofosbuvir is used at
a 400-mg daily dosage in patients with GFR
above 30 ml/min/1.73 m2. However, the
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authors tested a full dose or half dose of
sofosbuvir in stage 4 or 5 patients (on dialysis
or not) despite the exclusive renal elimination
pathway [71, 72]. They showed no
discontinuation due to side effects and no
significant adverse events in small groups of
patients. These results need to be confirmed in
larger populations of CKD patients.
Despite better efficacy and good tolerance in
CKD patients, DAAs may not be available, and
depending on the local conditions, older
therapies such as PEG-interferons could still be
offered with much less chance of SVR but at a
lesser cost.
Other oral DDA combinations may be used
in renal patients based on their hepatic
metabolism. The risk of renal pharmacokinetic
modifications in cirrhotic patients is high, and
DAAs with hepatic metabolism in this context
may not guarantee renal safety.
The HCV lifecycle can be blocked at many
steps. HCV DAAs on the market or in clinical
Table 2 Recent published guidelines for use of DAAs in CKD patients with comments from the latest publications
AASLD 2015
For patients with mild to moderate renal impairment (GFR[30–80 ml/min), no dosage adjustment is required when
using sofosbuvir, simeprevir, a ﬁxed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) or ﬁxed-dose
combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir
(250 mg) to treat or retreat HCV infection in patients with appropriate genotypes (I-A)
For treatment-naive patients with HCV genotype 1 without cirrhosis with GFR\30 ml/min, treatment with the daily
ﬁxed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed
dasabuvir (250 mg) with (1a) or without (1b) RBV (200 mg) once daily is recommended
RBV should only be given if the baseline hemoglobin level is greater than 10 g/dl
For patients with moderate renal impairment (eGFR 30–50 ml/min), initial RBV dosing should be 200 or 400 mg
alternating every other day
For patients with severe renal impairment or who are on hemodialysis (eGFR\30 ml/min), initial RBV dosing should
be 200 mg daily (II-B)
EASL 2015 Hepatitis C guidelines in hemodialysis patients
Simeprevir, daclatasvir and the combination of ritonavir-boosted paritaprevir, ombitasvir and dasabuvir are cleared by
hepatic metabolism and can be used in patients with severe renal disease (A1)
Sofosbuvir should not be administered to patients with an eGFR\30 ml/min/1.73 m2 or with end-stage renal disease
until more data are available (B2)
The need for dose adjustments for the approved HCV DAAs in patients on dialysis is unknown. No safety dosing and
efﬁcacy data are available in this population
These drugs should thus be used with extreme caution in patients with severe renal disease and only in extreme
life-threatening situations for patients on dialysis (B1)
Hemodialysis patients, particularly those who are suitable candidates for renal transplantation, should be considered for
antiviral therapy (B1)
Hemodialysis patients should receive an IFN-free, if possible ribavirin-free regimen for 12 weeks in patients without
cirrhosis, for 24 weeks in patients with cirrhosis (B1)
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development include NS3-4A protease
inhibitors, nucleotide analog inhibitors of
HCV RNA-dependent RNA polymerase (RdRp),
non-nucleoside inhibitors of HCV RdRp and
inhibitors of the non-structural 5A (NS5A)
protein. These drugs differ in their activity
against the different HCV genotypes and their
barrier to resistance. They also differ in terms of
the hepatic and renal metabolism. Some good
reviews offer tables that detail drug dosage
adaptations in renal failure [73]. In Table 1, we
give a recent update of DAA use in renal
patients. However, many other studies are
ongoing that will allow a better knowledge of
their safety in real-life conditions. New
guidelines have been released with regard to
hepatitis C treatment from both European and
American societies (Table 2).
Unsolved Questions
In the context of HCV-CryoVas, considering the
very rapid and potent virological efficacy of the
new DAA combination (i.e., SVR[95%, viremia
negative in\4 weeks) and the well-demonstrated
correlation between SVR and clinical response,
the exact place of rituximab, plasmapheresis or
other immunosuppressive drugs remains to be
defined.
In the context of a chronic renal
insufficiency in HCV-infected patients not
related to HCV-CryoVas, the role and impact
of new DAA combinations on kidney function
should be analyzed in large prospective studies
with mid- and long-term follow-up, including
GFR, proteinuria and hematuria.
CONCLUSION
New DAAs make the future of patients living
with hepatitis C very exciting with a promise
of a cure from the viral infection. Major
challenges for the clinicians remain optimal
use of the new drugs and further monitoring of
chronic kidney disease patients living with
sustained viral response to ensure long-term
renal protection.
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